GlaxoSmithKline - Alacra

APPENDIX AGlaxoSmithKline - Positions on Legislation - By MapLight - May 7, 2012Merck & Co., Inc.Messy Face Designs, Inc.Michael Stern PhotographyMicroRam Electronics, Inc.Minor League BaseballMinter Works of ArtMira ImagesMob Scene Creative ProductionsMonster Cable Products, Inc.Moose’s PhotosMorningstar Films LLCMotion Picture Association of America, Inc. (MPAA)MotionMastersMotor & Equipment Manufacturers AssociationMPA - The Association of Magazine MediaMr. Theodor Feibel (sole proprietor)Music Managers Forum-U.S.Nashville Songwriters Association InternationalNatalie Neckyfarow Actor/Dancer/SingerNational Association of BroadcastersNational Association of ManufacturersNational Association of Music MerchantsNational Association of Recording Merchandisers (NARM)National Association of Theatre Owners (NATO)National Basketball Association (NBA)National Board for Certified CounselorsNational Board for Certified Counselors FoundationNational Confectioners AssociationNational Electrical Manufacturers Association (NEMA)National Football League (NFL)National Music Publishers' Association (NMPA)National Retail Federation (NRF)NBCUniversalNervous Tattoo Inc., dba Ed HardyNew Balance Athletic Shoe, Inc.New Era Cap Co IncNew Levels Ent. Co. LLCNews CorporationNext Decade Entertainment, Inc.NHL Enterprises, L.P.Page 9

APPENDIX AGlaxoSmithKline - Positions on Legislation - By MapLight - May 7, 2012Nicholas Petrucci, Artist, LLCNike, Inc.Nintendo of America Inc.Nissle Fine Art PhotographyNorth Dakota Pharmacists AssociationNorth Dakota Pharmacy Service CorporationOakley, Inc.One Voice RecordingsOpSec Security, Inc.Outdoor Industry AssociationOutdoor Power Equipment Institute (OPEI)Outdoor Research, IncPacific Component Xchange, Inc.Party Killer Films LLCPearson Clinical AssessmentPeavey Electronics CorporationPerry Ellis InternationalPersonal Care Products CouncilPeter C. Brandt, Architectural and Fine Art PhotographyPeter Hawkins Photography, Inc.Petzl AmericaPfizer Inc.PGA of AmericaPhilip Morris InternationalPhotojournalist Dave BartruffPicture Archive Council of America (PACA)Pigfactory MusicPINGPNW ImagesPremier LeagueProduction Music Association (PMA)Professional Photographers of AmericaQuality Float Works, Inc.Raging Waters MusicRalph Lauren CorporationRamsay CorporationRebel PhotoRecording Industry Association of America (RIAA)Red Wing Shoe CompanyRed4 Music/Doogs Rock IncPage 10

APPENDIX AGlaxoSmithKline - Positions on Legislation - By MapLight - May 7, 2012Reebok International Ltd.Reed Elsevier Inc.Renie DesignRetail Industry Leaders Association (RILA)Reverb ProductionsRevlonRichard Flutie PhotographyRite AidRobin Davis Photography, Inc.Rodger Scott Craig, a member of Liverpool Express, The Merseybeats, Fortune, Harlan Cage,101 South, and Mtunz MediaRoger Smith Photography ServicesRolex Watch USA Inc.Romance Writers of America (RWA)Romin, Inc.Rosenthal Consulting LLCRosetta Stone Inc.Saddle CreekSage Studios LLCSam D'Amico PhotographySchneider ElectricSean McGinty PhotographySecret Sea Visions (Photography)SESAC, Inc.SG Industries, Inc.Shure IncorporatedSIGMA Assessment SystemsSix Degrees RecordsSmall Business & Entrepreneurship CouncilSMC EntertainmentSMT Corp.SoBe EntertainmentSoccer United MarketingSociety of Sport & Event PhotographersSoftware & Information Industry Association (SIIA)Sony Electronics Inc.Sony Music EntertainmentSony Pictures EntertainmentSoul Appeal Records and MusicSoundExchangePage 11

APPENDIX AGlaxoSmithKline - Positions on Legislation - By MapLight - May 7, 2012Southern Gothic LLCSpecialty Equipment Market Association (SEMA)SPI (The Plastics Industry Trade Association)Sporting Goods Manufacturers AssociationSports Rights Owners CoalitionSpring Fever Productions LLCSpyder Active Sports, IncStenbakken PhotographyStephen Dantzig PhotographyStock Artists AllianceStuart Weitzman Holdings, LLCStudent Photographic SocietyStudio 404SunRise Solar Inc.Taylor Glenn PhotographsTaylor GuitarsTaylor Made Golf Company, Inc.TechnicolorTednologies, Inc.The Cambridge DonThe Collegiate Licensing Company/IMG CollegeThe Donath Group, Inc.The Dow Chemical CompanyThe DVD Cafe'The EMI GroupThe Estee Lauder CompaniesThe McGraw-Hill CompaniesThe Music People! Inc.The National Collegiate Athletic Association (NCAA)The Nielsen Co.The Recording Academy (National Academy of Recording Arts and Sciences)The Timberland CompanyThe Walt Disney CompanyTiffany & Co.Tighe Creative Solutions, Inc.Time Warner Inc.Tony Bullard PhotographyToshiba America Business Solutions, Inc.TRA GlobalTrailer ParkPage 12

APPENDIX AGlaxoSmithKline - Positions on Legislation - By MapLight - May 7, 2012Tricoast WorldwideTrio Productions, Inc. / Songscape Music,Twist & Shout, Inc.U.S. Chamber of CommerceUltimate Fighting ChampionshipUnder ArmourUnderwriters Laboratories Inc.United States Tennis AssociationUniversal Music GroupUniweld Products Inc.VF CorporationViacomVibram USA, IncVictorinox Swiss Army, Inc.Virtual Chip Exchange USA, Inc.Voltage Pictures, LLCW.R. Case & Sons Cutlery Co.Walcott Studio, LLCWal-MartWarner Music GroupWendy Kaveney PhotographyWestern Psychological ServicesWestmorland Images, LLCWild & Associates, Inc.Wild Eye Photos LLCWilliam Sutton PhotographyWillis MusicWindLegends Ink LLCWinestem CompanyWinslow Research InstituteWolfe VideoWolverine World Wide, Inc.Woolrich, Inc.World Wrestling Entertainment, Inc.Xerox CorporationZippo Manufacturing CompanyZumba Fitness, LLCPage 13

APPENDIX BGlaxoSmithKline - Positions on Legislation - By MapLight - May 7, 2012Page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

APPENDIX BGlaxoSmithKline - Positions on Legislation - By MapLight - May 7, 2012Page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

APPENDIX CGlaxoSmithKline - Positions on Legislation - By MapLight - May 7, 2012Robert P. Casey Jr. United States Senator for Pennsylvania: Newsroom - .1 of 3Page id a8deb1ac-6ffd-424Robert P. Casey Jr.United States Senator for PennsylvaniaCasey Introduces Bipartisan Bill to Help Develop Treatments for Rare DiseasesThursday, March 17, 2011Printer-friendlyWASHINGTON, DC— U.S. Senator Bob Casey (D-PA) today introduced the Creating Hope Act of2011, a bipartisan bill that would encourage the development of new treatments for rare andneglected diseases that disproportionately affect children. The bill, which also has broad supportamong the medical community, patient advocates and biopharmaceutical companies, wouldstrengthen a cost-neutral FDA program giving biopharmaceutical companies an incentive to developtreatments for rare diseases that are often less profitable than treatments for more common medicalconditions.“Millions of Americans are affected by rare diseases and neglected conditions for which there iscurrently no hope because there is no treatment,” said Senator Casey. “The Creating Hope Actbrings light where there is now only darkness by providing an incentive, at no cost to taxpayers, todevelop treatments for these illnesses. The broad support for this legislation speaks to the need tosolve this problem.”The Creating Hope Act is cosponsored by Senators Scott Brown (R-MA), Sherrod Brown (D-OH), AlFranken (D-MN) and Johnny Isakson (R-GA).Rare diseases, such as pediatric cancers, and neglected tropical diseases, such as malaria, affectsignificant numbers of Americans and people around the globe. More than 20 million Americanshave a rare disease, according to the National Organization for Rare Disorders. An estimated onebillion people worldwide suffer from a neglected tropical disease according to the World HealthOrganization, and children are most frequently and profoundly affected by these conditions.“I applaud Senator Casey’s leadership in introducing the Creating Hope Act,” said Nancy Goodman,Executive Director of Kids v. Cancer. “I want to ensure that one day, children like my son, Jacob,who are diagnosed with brain cancer and other serious and rare diseases, will have drugs availablefor safe and effective treatments.”Peter C. Adamson, M.D., Chair of the Children’s Oncology Group at the Children’s Hospital ofPhiladelphia, said: “I commend Senator Casey and his colleagues for introducing the Creating HopeAct of 2011. As a pediatric oncologist who leads the Children’s Oncology Group, a nationwide teamof physicians, scientists, nurses and others dedicated to treating children with cancer, I know thatimproving the outcome for children with cancer will require development of new, more effective7/15/2011 11:37

APPENDIX CGlaxoSmithKline - Positions on Legislation - By MapLight - May 7, 2012Robert P. Casey Jr. United States Senator for Pennsylvania: Newsroom - .2 of 3Page id a8deb1ac-6ffd-424anti-cancer drugs. With cancer remaining the leading cause of disease related death in children inthe United States, the Creating Hope Act of 2011 will provide a critically important new way to helpengage scientists in the biopharmaceutical industry to help develop better medicines for the childrenwe care for.”“Long a pioneer in pediatric medical research, Children’s Hospital of Pittsburgh of UPMC iscommitted to seeking new and innovative therapies for the cure of childhood diseases and disability– no matter how rare,’’ said David H. Perlmutter, MD, Physician-in-Chief and Scientific Director.“Creating incentives for companies to invest in new treatments will help ensure our continuedadvancement in providing the most exceptional medical care for the most vulnerable children.”“Of the nearly one in 10 Americans with rare diseases, approximately two-thirds are children,” saidPeter L. Saltonstall, President and CEO of the National Organization for Rare Disorders (NORD).“Many of these rare pediatric diseases are very serious and treatments are desperately needed. Byexpanding priority review vouchers to include pediatric rare diseases, this legislation wouldencourage the development of treatments for children with serious rare diseases.”“Pennsylvania Bio thanks Senator Casey for his continued commitment to the life sciences industryand the thousands of patients in the United States who suffer from rare diseases,” statedChristopher P. Molineaux, President, Pennsylvania Bio. “With nearly 7,000 rare diseases, defined asdiseases affecting 200,000 or fewer Americans, few treatment options exist for these small patientpopulations because it is often prohibitive for companies to enter the rare disease marketplace.Pennsylvania Bio encourages members of the 112th Congress to follow Senator Casey’s lead andtake the necessary steps to support corporations who are conducting research into treatments forthese rare diseases, many of which affect children.”Despite this significant unmet medical need, private companies seldom pursue new therapies fortropical illnesses or rare diseases because it requires making an investment in products that willlikely not recoup the high costs associated with their research, development, marketing anddistribution. Developing products for children is particularly challenging because of the difficultiesassociated with conducting clinical trials on this population.Currently, pharmaceutical companies can receive a priority review voucher (PRV) if they developnovel treatments for neglected tropical diseases, entitling the company to a priority six month reviewof another new drug application that would otherwise be reviewed under the FDA’s standard tenmonth review period. This shortened review time, which can lead to earlier market entry, is estimatedto be worth hundreds of millions of dollars.The Creating Hope Act of 2011 will build on the PRV program to create a stronger incentive forcompanies to invest in new treatments for rare diseases affecting children and neglected tropical7/15/2011 11:37

APPENDIX CGlaxoSmithKline - Positions on Legislation - By MapLight - May 7, 2012Robert P. Casey Jr. United States Senator for Pennsylvania: Newsroom - .3 of 3Page id a8deb1ac-6ffd-424diseases. This legislation will: Expand priority review vouchers to include treatments for pediatric rare diseases, so thatthere is greater incentive to close the devastating treatment gap for kids. Close a loophole in current law to prevent companies from receiving a voucher for productsthat they already market in other countries. Offer unlimited transferability of vouchers to create a more easily-traded asset. Provide greater certainty to sponsors by permitting them to seek a designation from FDAbefore they submit their new drug application that the drug, if approved, will qualify for a voucher. Strengthen reporting and marketing requirements by requiring that the sponsor submit astatement of good faith intent to market the eligible drug. Add Chagas disease, which is responsible for more deaths in Central and South Americathan every other parasite-borne disease, to FDA’s list of neglected tropical diseases.The following groups and businesses have endorsed the legislation: Aeras Global TB VaccineFoundation, Association of Pediatric Oncology Social Workers, American Society of ClinicalOncology, American Society of Pediatric Hematology and Oncology, American Society for TropicalMedicine and Hygiene (ASTMH), Bio Ventures for Global Health, Chai Lifeline, Children's BrainTumor Foundation, Children’s Hospital of Philadelphia, Children’s Hospital of Pittsburgh of UPMC,CureSearch, GlaxoSmithKline, Genzyme, Kids v Cancer, Leukemia & Lymphoma Society, TheNational Association of Children’s Hospitals, The National Children's Cancer Society, NationalOrganization for Rare Disorders, Novartis, Medicines for Malaria Venture (MMV), Merck, Metronomix,Sarcoma Foundation of America, Pennsylvania BIO, Shire, CSL Behring, TB Alliance.###7/15/2011 11:37

APPENDIX DGlaxoSmithKline - Positions on Legislation - By MapLight - May 7, 2012For Immediate ReleaseMarch 8, 2011Page 19Contact: Bill Mashek202.354.8275bmashek@pstrategies.comAmerica Invents Act Boosts Innovation and Jobs, Strengthens Patent SystemCoalition Appreciates Bipartisan Support in Senate and Looks Forward to House ActionWashington, D.C. – After the U.S. Senate’s overwhelming vote this evening to adopt S. 23, TheAmerica Invents Act, Gary Griswold of the Coalition for 21st Century Patent Reform released thefollowing statement:“With the approval of S. 23, The America Invents Act, the U.S. Senate has moved the nationforward in promoting innovation, protecting inventions and enhancing the operations of the U.S.Patent and Trademark Office. The bipartisan leadership of Chairman Leahy, Senators Grassley,Hatch, Kyl, Klobuchar and others, as well as the efforts of the Administration, were instrumentalin securing such a strong vote for helping America’s inventors.As amended, S. 23 answers the call of American innovators because this bill will give the USPTOthe tools and funding it needs to process patents in a more effective and efficient way. Accordingly,this legislation will make our nation more competitive in the global marketplace and set in placerules that will benefit the next generation of inventors. It is clear that the 112th Congress wants topromote innovation and create jobs; adoption of S. 23 is a major step forward in achieving thesegoals. It is very encouraging that the members of the House and Senate have been in discussions onthe issue and that the House Judiciary Committee is actively moving ahead with its consideration ofpatent reform. Our Coalition looks forward to continuing to work with members of the Senate andthe House to produce fair and balanced patent reform legislation.”-- 30 --The Coalition has approximately 50 members from 18 diverse industry sectors and includes many of thenation’s leading manufacturers and resear

National Association of Broadcasters National Association of Manufacturers National Association of Music Merchants National Association of Recording Merchandisers (NARM) National Association of Theatre Owners (NATO) National Basketball Associa